Clinical Pharmacology Organic Chemistry Treatment 
Drug Target Review
JULY 4, 2023
These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. ADCs have the potential to redress the poor balance between safety and efficacy seen with traditional cancer treatment options.
Drug Discovery World
NOVEMBER 8, 2023
Adams, on a first-in-human study of ELU001, a targeted c’dot drug conjugate, in subjects with folate receptor α (frα) overexpressing solid tumours, and Groothuis on the non-clinical pharmacology of the MET-targeting ADC BYON3521. Phil Jones, VP Discovery, RxBiologics, on: ‘Antibody discovery using the Galaxy library platform’.
Expert insights. Personalized for you.
145 
Let's personalize your content